Clinical trial

Role of the Environment in Pediatric Obesity

Opening soon · Not applicable · 1 countries · Registry ID NCT07545174

Opening soonNot applicableInterventional

What this study is about

Childhood obesity is a particular concern in developed countries such as the United States, the United Kingdom, Canada, and certain European countries. According to the World Health Organization (WHO), approximately 6% of children under the age of 5 worldwide were obese in 2016, a figure that continues to rise. The pathophysiology of pediatric obesity can be explained by several interconnected biological and behavioral mechanisms. In particular, it involves dysfunctions in the hormones that regulate appetite and satiety, as well as dysfunctions in lipid metabolism. Per- and polyfluoroalkyl substances (PFAS) are a large family of synthetic chemical compounds. The main PFAS are perfluorooctanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS), perfluorononanoic acid (PFNA), and perfluorohexanesulfonic acid (PFHxS). PFAS are present in many everyday consumer products. Bisphenol A (BPA) is a chemical compound used primarily in the manufacture of plastics and resins. It is commonly found in polycarbonate plastics, used to make food containers and water bottles, as well as in epoxy resins, which are used to coat the inside of food cans and water pipes. Non-persistent pesticides, such as organophosphates and polychlorinated biphenyls, are chemicals used primarily in agriculture to control insects and other pests. There are arguments suggesting that PFAS, bisphenol A, and non-persistent pesticides may play a role in the onset of pediatric obesity, particularly by acting.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age6 Years to 15 Years
SexAll
Healthy volunteersAccepted
ConditionObesity (Disorder)

Full registry criteria

Inclusion Criteria: Patient with Obesity disorder : * Children with obesity (according to the BMI curves of the International Obesity Task Force/IOTF) * Follow-up within the obesity network of the Centre Val de Loire region (ObeCentre) Control group: * Children who are not obese (according to the BMI curves of the International Obesity Task Force/IOTF) All: * Children aged 6 to 15 at the time of inclusion (inclusive) * Whose two parents, or legal guardian, have signed an informed consent form * Patients affiliated with or covered by a social security system Exclusion Criteria: * Disorder preventing understanding of trial information or informed consent.

Treatments and study arms

Blood test

Other

Inclusion visit: during the routine blood test, one additional tube of blood will be collected for the study.

Urine sample

Other

Inclusion visit: a urine sample will be collected for the study.

Hair sample

Other

Inclusion visit: a hair sample will be taken from the patient.

Primary outcomes

PFOA concentrationAt the enrollment visit

Difference in plasma PFOA concentration measured in ng/mL between obese and non-obese children (control group). PFOA will be measured in plasma using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) at the Laberca laboratory.

Study locations

2 locations were listed when this page was built. The first 40 are shown.

CHRU de Tours🇫🇷 Tours, France
Julien LEJEUNEContact
Julien LEJEUNEPrincipal Investigator
CHRU de Tours🇫🇷 Tours, France
Karine BERNARDOContact
Karine BERNARDOPrincipal Investigator